Skip to main content
Explore URMC
menu

Karlo J. Lizarraga Mendoza, M.D., M.S.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

  • Assistant Professor - Department of Neurology , Movement Disorders (SMD)
  • Assistant Professor - Center for Health and Technology - Joint

Patient Care Setting

Neurology

Biography

Professional Background

Dr. Lizarraga is a board certified neurologist and clinical neurophysiologist with expertise in movement disorders, motor physiology and neuromodulation. Dr. Lizarraga is assistant professor at the department of neurology and the center for health + technology at our institution. He is also invited professor of the department of neurosciences at the Universidad Nacional de San Agustín in Arequipa, Peru.

Dr. Lizarraga is chief of our division of movement disorders, director (founder) of the motor physiology and neuromodulation program and director (founder) of the Neurology Peru-Rochester exchange program (NeuroPro). His career goals are to optimize the understanding, diagnosis and treatment of movement disorders with the use of neurophysiological techniques, and to develop sustainable international collaborations that promote global equity in neurological education, research and patient care.

Credentials

Specialties

  • Clinical Neurophysiology - American Board of Psychiatry and Neurology
  • Neurology - American Board of Psychiatry and Neurology

Education

2008
MD | Universidad Nacional de San Agustin

2012
MS | Universidad Nacional de San Agustin

2021
MS | Medical University of South Carolina
Clinical Research

Post-doctoral Training & Residency

07/01/2016 - 06/30/2017
Fellowship in Clinical Neurophysiology at Jackson Memorial Hospital

07/01/2013 - 06/30/2016
Residency in Neurology at Jackson Memorial Hospital

06/01/2010 - 04/30/2012
Research in Functional and Stereotactic Neurosurgery at University of California Los Angeles

8/4/2017 - 06/30/2019
Fellowship in Movement Disorders at Toronto Western Hospital

06/1/2012 - 06/30/2013
Internship in Neurology at Jackson Memorial Hospital

VIEW ALL expand_more

Awards

2021 - Present
Leadership Program (MDS LEAP)
Sponsor: International Parkinson and Movement Disorders Society

2020 - 2021
Emerging Leaders Program
Sponsor: American Academy of Neurology

2018 - 2021
TRANSCENDS Scholar
Sponsor: AAN / MUSC (NIH R25: NS098999-01)

2018 - 2019
Fellowship Award
Sponsor: Dystonia Medical Research Foundation
Location: Canada

2017 - 2017
Clinical Trials Methodology Course
Sponsor: NINDS (NIH R25: NS088248)

VIEW ALL expand_more

Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls

Lead Researcher: Karlo J Lizarraga mendoza

It is hoped that TAK-071 will help people with Parkinson's disease to walk with better balance. The main aim of the study is to check if there is a difference in how participants walk after treatment with TAK-071. Another aim is to see if it improves how participants think and remember. At the first visit, the study doctor will check who can take part. Participants who can take part will be picked for 1 of 2 groups by chance. Both groups will have 2 treatments but in a different order. The treatments are TAK-071 tablets or placebo. In this study, a placebo will look like the TAK-071 but will not have any medicine in it. One group will take TAK-071 for 6 weeks, have at least a 3-week break, then take a placebo for 6 weeks. The other group will take a placebo for 6 weeks, have at least a 3-week break, then take TAK-071 for 6 weeks. The participants will not know the order of their 2 treatments, nor will their study doctors. This is to help make sure the results are more reliable. The participants will visit the clinic at the beginning and end of each treatment for a check-up. 14 days after the 2nd treatment, clinic staff will telephone the participants for a final check-up.

View Study Details

Publications

Journal Articles

2/13/2022
Lizárraga KJ, Gnanamanogaran B, Al-Ozzi TM, Cohn M, Tomlinson G, Boutet A, Elias GJB, Germann J, Soh D, Kalia SK, Hodaie M, Munhoz RP, Marras C, Hutchison WD, Lozano AM, Lang AE, Fasano A. "Lateralized Subthalamic Stimulation for Axial Dysfunction in Parkinson's Disease: A Randomized Trial." Movement disorders : official journal of the Movement Disorder Society.. 2022 Feb 13; Epub 2022 Feb 13.

12/2021
Tarolli CG, Lizarraga KJ. "Approach to the Patient with Gait Disturbance." Seminars in neurology.. 2021 Dec 0; 41(6):717-730. Epub 2021 Nov 26.

11/2021
Zumaeta K, Romero SE, Torres E, Urdiales L, Ramirez A, Camargo I, Lizarraga KJ, Castaneda B. "Combining inertial sensors and optical flow to assess finger movements: Pilot study for telehealth applications." . 2021 Nov 0; 2021:2409-2412.

Books & Chapters

2017
Chapter Title: Subacute Sclerosing Panencephalitis
Book Title: Reference Module in Neuroscience and Biobehavioral Psychology
Author List: Lizarraga KJ, Gutierrez J, Singer C
Published By: El Sevier 2017

2016
Chapter Title: Molecular Imaging of the Brain with PET
Book Title: Youmans and Winn Neurological Surgery
Author List: DeSalles AA, Lizarraga KJ, Gorgulho A, Melega WP
Published By: El Sevier 2016

2013
Chapter Title: Applications of Nanotechnology in Movement Disorders
Book Title: The Textbook of Nanoneuroscience and Nanoneurosurgery
Author List: Pezeshkian P, Lizarraga KJ, Gorgulho A, DeSalles AF
Published By: CRC Press 2013

VIEW ALL PUBLICATIONS